Cystone®
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Cystone® - phytopreparation with diuretic, litholytic and anti-inflammatory action.
The drug regulates the crystal-colloidal balance in dismetabolic nephropathy, reduces the concentration in the urine of elements that contribute to the formation of stones (oxalic acid, calcium, hydroxyproline). Increases the level of elements that inhibit the formation of stones (sodium, magnesium, potassium). Influencing mucin, the drug contributes to the disintegration of stones, leading to their demineralization.
It prevents the accumulation of particles around the core of the stone, which prevents its further growth.
By stimulating diuresis and relaxing the smooth muscles of the urinary tract, Cystone® promotes the elimination of oxalate and phosphate salts, uric acid and small stones from the urinary tract.
Cystone® has a bacteriostatic and bactericidal effect, especially in relation to Klebsiella spp., Pseudomonas aeruginosa, Escherichia coli and other gram-negative bacteria.
The litholytic effect of the drug does not depend on the urine pH.
Indications
In the complex therapy:
- urolithiasis,
- crystalluria,
- urinary tract infections,
- gout.
Composition
1 tablet contains:
active substances: extract of Didimocarpus stalk flowers - 65 mg; extract of stalks of saxweed reed - 49 mg; extract of the stalk of the madder heart - 16 mg; rhizome extract syty filmy - 16 mg; extract of seeds of rough strawberry - 16 mg; extract of the aerial part of the onosma prismous - 16 mg; extract of whole plant Vernonia ashy - 16 mg; Mumiyo powder purified - 13 mg; silicate lime powder - 16 mg;
processed over the steam extract of a mixture of plant materials of the aerial parts of fragrant basil, horse bean seeds, creeping yakornetsy fruits, shy, mimosa seeds, fragrant, whole pavony plant, whole horsetail plant, teak seed;
Excipients: magnesium stearate MCC, sodium carboxymethylcellulose, crospovidone, aerosil (colloidal silicon dioxide).
No customer reviews for the moment.
Dosage and Administration
The use of the drug Cystone® is recommended inside, after a meal on the background of increased fluid intake up to 2-2.5 liters per day.
Adults: complex therapy of urolithiasis and crystalluria: 2 pills 2 times a day for 4-6 months or until stones are released; prevention of relapse after surgical removal, remote lithotripsy or spontaneous release of stones: 2 pills 2 times a day for the first month, then 1 tablet 2 times a day for 4-5 months; complex therapy of urinary tract infections (cystitis, urethritis, pyelonephritis and others): 2 pills 2 times a day, the duration of treatment is 2-3 weeks or until normalization of clinical symptoms and laboratory tests.
The duration of treatment may be extended depending on the severity of the disease on the advice of a doctor.
Adverse reactions
Allergic reactions.
If any of the side effects indicated in the instruction are aggravated, or you notice any other side effects not indicated in the instruction, inform your doctor.
Contraindications
- Acute pain in the kidneys and urinary tract.
- Age up to 18 years.
- It is not recommended to use the drug when the size of stones is more than 9 mm in diameter due to the threat of obstruction.
- Hypersensitivity to the drug.
Drug interactions
The use of the drug with antibiotics contributes to the effectiveness of therapy. Cystone® increases the bioavailability of norfloxacin. When combined with co-trioxazole in an animal experiment, Cystone® delayed the absorption of sulfamethoxazole, statistically significantly increasing its bioavailability, and accelerated the absorption of trimethoprim, without significantly affecting its bioavailability. When using these drugs simultaneously with the drug Cystone® may require correction of their dose.
Pregnancy and Lactation
Use of the drug is not recommended during pregnancy and lactation (due to the lack of data on the study of the effectiveness and safety of the drug in these conditions). If necessary, the use of the drug breastfeeding should be discontinued.
Special instructions
Since the therapeutic effect of the drug Cystone® develops gradually, it should be stopped if there is acute pain in the kidneys and urinary tract and consult a doctor.
The use of the drug in urolithiasis requires compliance with a diet with a restriction in the diet of nutrients that contribute to the formation of salt crystals or stones in the urinary tract, and taking into account the peculiarities of the metabolism and acid-base reaction of urine.
The use of the drug in urolithiasis and crystalluria does not depend on the composition of stones and urine pH. The drug is effective in oxalate, urate, phosphate urolithiasis. If you discontinue taking the drug, Cystone® pills of "withdrawal" syndrome are not observed. Elderly patients and patients with renal insufficiency do not require dose adjustment. Special measures when skipping one or more doses of the drug is not required. If the patient misses taking the drug one or several times, the drug should be continued as recommended in the instructions, without doubling the dose. Special precautions when destroying unused medicinal product is not required.
Overdosage
To avoid overdose, strictly follow the instructions for use. Treatment in the event of an accidental overdose with Cystone®: symptomatic. To date, overdose cases have not been identified, therefore, overdose symptoms have not been described.
- Effect of cystone, a herbal formulation, on glycolic acid-induced urolithiasis in rats
- Cystone®for 1
- Cystone in cystine stone formers
- Effect of Cystone® on urinary composition and stone formation over a one year period
- Protective effects of cystone, a polyherbal ayurvedic preparation, on cisplatin-induced renal toxicity in rats
- Reduction of cisplatin-induced nephrotoxicity by cystone, a polyherbal ayurvedic preparation, in C57BL/6J mice bearing B16F1 melanoma without reducing its antitumor activity
- Evaluation of an Ayurvedic formulation (Cystone), in urolithiasis: A double blind, placebo-controlled study
- Evaluation of the protective effect of Cystone®against cisplatin-induced nephrotoxicity in cancer patients, and its influence on cisplatin antitumor activity
- Safety and Efficacy of an Ayurvedic Formulation Cystone in Management of Ureteric Calculi: A Prospective Randomized Placebo Controlled Study